Goldman’s foray into the biotech world shows continuing investor appetite in the venture capital arena, even while the public biotech market remains tepid. The last year featured a number of new VC fund launches, including from Dimension, Cure Ventures, Yosemite, Foundery and Bioluminescence Ventures.
“The current environment provides an attractive opportunity for investing,” Amit Sinha, the head of Goldman’s Life Sciences Investing, said in the company’s statement. Technological advances are allowing new ways to attack diseases, creating a “golden era” for life sciences, he said.
